Unicycive Therapeutics Inc
UNCY
Get informed when a big investor buys or sells
+ FollowMarket Cap$128.16M
Close$
$1.83
62.1% downside
Current Fair Value
62.1% downsideOvervalued by 62.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $128.16 Million |
|---|---|
| Enterprise Value | $84.65 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.67 |
| Beta | 1.78 |
| Outstanding Shares | 26,917,266 |
Return
| Return on Equity | -66.12% |
|---|---|
| Return on Assets | -48.90% |
| Return on Invested Capital | -57.75% |
Valuation & Multiples
| P/E Ratio | -2.87 |
|---|---|
| PEG | 3.91 |
| Price to Sales | - |
| Price to Book Ratio | 4.81 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.75 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.53
Average shareholder expectationRevenue Estimate
$22.22 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$902,778
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3837▼ 280.11% |
|---|---|
| Total Calls | 1,671,423▲ 1083.73% |
| Total Puts | 641,400▲ 42.63% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 43.34%▲ 1.91% |
|---|---|
| Total Invested | $54.82M▼ 15.93% |
| Investors Holding | 90▲ 33.00% |
ESG Score
No data